ct041
carsgen therapeutics
['ct041', 'car t']
carsgen therapeutics (stock code: presented two posters with study results for ct041, an autologous car t-cell product candidate against protein claudin18.2 (cldn18.2) at asco 2022. 
Biotechnology news and information from PR Newswire. Some paid tweets will appear.